NCT00514917 - A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA) | Biotech Hunter

Enrollment

413

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions

Prostatic Neoplasms

Interventions

DRUG

Docetaxel

75 mg/m\^2 intravenous infusion over 1 hour every 3 weeks up to 10 cycles.

DRUG

Leuprolide

22.5 mg injection subcutaneously every 12 weeks up to 18 months.

DRUG

Bicalutamide

50 mg tablet orally once daily for first 4 weeks of treatment.

Trial Locations (9)

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Prague

Sanofi-Aventis Administrative Office, Frankfurt

Sanofi-Aventis Administrative Office, Vilnius

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, Bratislava

Sanofi-Aventis Administrative Office, Barcelona